Frederik J R Rombouts

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8131793/publications.pdf

Version: 2024-02-01

		567281	526287
27	737	15	27
papers	citations	h-index	g-index
31	31	31	1080
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Expedient Access to Cyanated Nâ€Heterocycles by Direct Flowâ€Electrochemical C(sp ²)â^'H Activation. Chemistry - A European Journal, 2022, 28, .	3.3	4
2	Modulating physicochemical properties of tetrahydropyridine-2-amine BACE1 inhibitors with electron-withdrawing groups: A systematic study. European Journal of Medicinal Chemistry, 2022, 228, 114028.	5. 5	0
3	A Brain-Penetrant and Bioavailable Pyrazolopiperazine BACE1 Inhibitor Elicits Sustained Reduction of Amyloid \hat{I}^2 In Vivo. ACS Medicinal Chemistry Letters, 2022, 13, 76-83.	2.8	3
4	Small-molecule BACE1 inhibitors: a patent literature review (2011 to 2020). Expert Opinion on Therapeutic Patents, 2021, 31, 25-52.	5.0	22
5	Structure-Based Approaches to Improving Selectivity through Utilizing Explicit Water Molecules: Discovery of Selective β-Secretase (BACE1) Inhibitors over BACE2. Journal of Medicinal Chemistry, 2021, 64, 3075-3085.	6.4	11
6	JNJ-67569762, A 2-Aminotetrahydropyridine-Based Selective BACE1 Inhibitor Targeting the S3 Pocket: From Discovery to Clinical Candidate. Journal of Medicinal Chemistry, 2021, 64, 14175-14191.	6.4	10
7	Discovery of Extremely Selective Fused Pyridine-Derived \hat{l}^2 -Site Amyloid Precursor Protein-Cleaving Enzyme (BACE1) Inhibitors with High In Vivo Efficacy through 10s Loop Interactions. Journal of Medicinal Chemistry, 2021, 64, 14165-14174.	6.4	4
8	Clinical evaluation of [18F] JNJ-64326067, a novel candidate PET tracer for the detection of tau pathology in Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 3176-3185.	6.4	17
9	3,3-Difluoro-3,4,5,6-tetrahydropyridin-2-amines: Potent and permeable BACE-1 inhibitors. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 126999.	2.2	3
10	Evaluation of a Series of \hat{l}^2 -Secretase 1 Inhibitors Containing Novel Heteroaryl-Fused-Piperazine Amidine Warheads. ACS Medicinal Chemistry Letters, 2019, 10, 1159-1165.	2.8	20
11	Discovery of <i>N</i> -(4-[¹⁸ F]Fluoro-5-methylpyridin-2-yl)isoquinolin-6-amine (JNJ-64326067), a New Promising Tau Positron Emission Tomography Imaging Tracer. Journal of Medicinal Chemistry, 2019, 62, 2974-2987.	6.4	24
12	New evolutions in the BACE1 inhibitor field from 2014 to 2018. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 761-777.	2.2	57
13	Optimization of 1,4-Oxazine \hat{l}^2 -Secretase 1 (BACE1) Inhibitors Toward a Clinical Candidate. Journal of Medicinal Chemistry, 2018, 61, 5292-5303.	6.4	15
14	Discovery of <i>N</i> -(Pyridin-4-yl)-1,5-naphthyridin-2-amines as Potential Tau Pathology PET Tracers for Alzheimer's Disease. Journal of Medicinal Chemistry, 2017, 60, 1272-1291.	6.4	31
15	Preclinical Evaluation of ^{18 < /sup>F-JNJ64349311, a Novel PET Tracer for Tau Imaging. Journal of Nuclear Medicine, 2017, 58, 975-981.}	5.0	72
16	Fragment Binding to \hat{l}^2 -Secretase 1 without Catalytic Aspartate Interactions Identified via Orthogonal Screening Approaches. ACS Omega, 2017, 2, 685-697.	3.5	14
17	Industrial medicinal chemistry insights: neuroscience hit generation at Janssen. Drug Discovery Today, 2017, 22, 1478-1488.	6.4	5
18	Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present). Expert Opinion on Therapeutic Patents, 2016, 26, 933-946.	5.0	22

#	ARTICLE	IF	CITATION
19	Synthesis of 2,1â€Borazaroquinolines and 2,1â€Borazaroisoquinolines from VinylÂaminopyridines and Potassium Organotrifluoroborates by Microwaveâ€Assisted Heating. European Journal of Organic Chemistry, 2015, 2015, 5221-5229.	2.4	17
20	Tau Positron Emission Tomography (PET) Imaging: Past, Present, and Future. Journal of Medicinal Chemistry, 2015, 58, 4365-4382.	6.4	88
21	Pyrido [4,3- <i>e</i>][1,2,4]triazolo [4,3- <i>a</i>]pyrazines as Selective, Brain Penetrant Phosphodiesterase 2 (PDE2) Inhibitors. ACS Medicinal Chemistry Letters, 2015, 6, 282-286.	2.8	49
22	1,4-Oxazine \hat{l}^2 -Secretase 1 (BACE1) Inhibitors: From Hit Generation to Orally Bioavailable Brain Penetrant Leads. Journal of Medicinal Chemistry, 2015, 58, 8216-8235.	6.4	67
23	Benzazaborinines as Novel Bioisosteric Replacements of Naphthalene: Propranolol as an Example. Journal of Medicinal Chemistry, 2015, 58, 9287-9295.	6.4	62
24	Structure-Based Design of a Potent, Selective, and Brain Penetrating PDE2 Inhibitor with Demonstrated Target Engagement. ACS Medicinal Chemistry Letters, 2014, 5, 1049-1053.	2.8	41
25	Regioselective Preparation of 3â€Alkoxyâ€4,5â€difluoroanilines by S _N Ar. European Journal of Organic Chemistry, 2012, 2012, 7048-7052.	2.4	7
26	Rational design and synthesis of aminopiperazinones as \hat{I}^2 -secretase (BACE) inhibitors. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 7255-7260.	2.2	44
27	Microwave-assisted N-debenzylation of amides with triflic acid. Tetrahedron Letters, 2010, 51, 4815-4818.	1.4	27